Efficacy and safety of chronic antimicrobial suppression therapy for left ventricular assist device driveline infections: A single‐center descriptive experience
Radcliffe C, Doilicho N, Niu YS, Grant M. Efficacy and safety of chronic antimicrobial suppression therapy for left ventricular assist device driveline infections: A single‐center descriptive experience. Transplant Infectious Disease 2020, 22: e13379. PMID: 32574417, DOI: 10.1111/tid.13379.Peer-Reviewed Original ResearchConceptsCAS therapyDriveline infectionSuppression therapyTreatment failureVentricular assist device driveline infectionsShort-term antimicrobial therapyExperienced treatment failureTertiary transplant centerChronic kidney diseaseCornerstone of managementContinuous-flow LVADInfectious complicationsAdverse eventsLocal debridementRetrospective reviewTransplant centersKidney diseaseStable symptomsMean ageAntimicrobial therapyCommon causePatientsTherapySuccessful outcomeInfectionNontuberculous mycobacterial infections in left ventricular assist device patients
Radcliffe C, Doilicho N, Grant M. Nontuberculous mycobacterial infections in left ventricular assist device patients. Journal Of Cardiac Surgery 2020, 35: 1138-1141. PMID: 32253770, DOI: 10.1111/jocs.14530.Peer-Reviewed Case Reports and Technical NotesConceptsNontuberculous mycobacterial infectionNTM infectionMycobacterial infectionLeft ventricular assist device patientsVentricular assist device patientsRefractory heart failureContinuous-flow LVADVentricular assist deviceLVAD infectionGram-negative enteric bacteriaLVAD patientsDevice patientsHeart failureDriveline infectionDevice exchangeMost infectionsClinical challengeNegative culturesAssist deviceSystematic reviewInfectionDevice placementMycobacterium fortuitumStaphylococcal sppPatients